oz-439 and Disease-Models--Animal

oz-439 has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for oz-439 and Disease-Models--Animal

ArticleYear
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
    Journal of medicinal chemistry, 2021, 05-27, Volume: 64, Issue:10

    Topics: Administration, Oral; Animals; Antimalarials; Cyclization; Disease Models, Animal; Ethers; Female; Half-Life; Hydrogen-Ion Concentration; Malaria; Mice; Mice, Inbred BALB C; Plasmodium falciparum; Prodrugs; Quinolones; Solubility; Structure-Activity Relationship

2021
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
    Bioorganic & medicinal chemistry, 2018, 07-15, Volume: 26, Issue:11

    A series of aryl carboxamide and benzylamino dispiro 1,2,4,5-tetraoxane analogues have been designed and synthesized in a short synthetic sequence from readily available starting materials. From this series of endoperoxides, molecules with in vitro IC50s versus Plasmodium falciparum (3D7) as low as 0.84 nM were identified. Based on an assessment of blood stability and in vitro microsomal stability, N205 (10a) was selected for rodent pharmacokinetic and in vivo antimalarial efficacy studies in the mouse Plasmodium berghei and Plasmodium falciparum Pf3D70087/N9 severe combined immunodeficiency (SCID) mouse models. The results indicate that the 4-benzylamino derivatives have excellent profiles with a representative of this series, N205, an excellent starting point for further lead optimization studies.

    Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Humans; Inhibitory Concentration 50; Malaria; Mice; Morpholines; Plasmodium falciparum; Rats; Tetraoxanes

2018